Abstract
Background: The choice of radiographic contrast media for use in patients at increased risk of contrast-induced nephropathy (CIN) is of ongoing interest. Methods: The current study is a prospective, multicenter, randomized, double-blind design comparing the renal effects of the non-ionic, iso-osmolal agent, iodixanol, versus the non-ionic, low-osmolal agent, iopamidol, in 526 subjects with impaired baseline renal function (chronic kidney disease) and diabetes mellitus undergoing diagnostic and/or therapeutic coronary angiographic procedures. The co-primary end points were the peak increase in serum creatinine (SCr) and the incidence of CIN (increase ≥0.5 mg/dL) in SCr from baseline within 3 days of receiving contrast media. Results: In 418 evaluable subjects with complete postcontrast media SCr data, the median peak increase in SCr in the iodixanol arm was 0.10 mg/dL, whereas in the iopamidol arm, the median peak increase was 0.09 mg/dL (P = .13). The overall CIN incidence was 10.5% (11.2% % in the iodixanol arm and 9.8% in the iopamidol arm, P = .7). The volume of contrast media, volume of saline administered, frequency of coronary interventional procedures, and severity of baseline kidney disease and of diabetes mellitus were similar between treatments. Conclusions: In the present study, the overall rate of CIN in patients with chronic kidney disease and DM undergoing coronary angiographic procedures was 10.5%. There was no significant difference between iodixanol and iopamidol in either peak increase in SCr or risk of CIN.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 822-828.e3 |
| Journal | American heart journal |
| Volume | 158 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2009 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures'. Together they form a unique fingerprint.
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. / Laskey, Warren; Aspelin, Peter; Davidson, Charles; Rudnick, Michael; Aubry, Pierre; Kumar, Sreenivas; Gietzen, Frank; Wiemer, Marcus.
In: American heart journal, Vol. 158, No. 5, 11.2009, p. 822-828.e3.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures
AU - Laskey, Warren
AU - Aspelin, Peter
AU - Davidson, Charles
AU - Rudnick, Michael
AU - Aubry, Pierre
AU - Kumar, Sreenivas
AU - Gietzen, Frank
AU - Wiemer, Marcus
N1 - Funding Information: Center no. Investigator/affiliation No. of subjects enrolled ⁎ /given CM 001 Prof Peter Aspelin † /Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden 6/6 002 Dr Knut Endresen/Dept of Cardiology, Rikshospitalet University Hospital, Sognsvannsveien 20, 0027 Oslo, Norway 1/0 003 Dr Victor Legrand/Service de Cardiologie, Centre Hospitalier Universitaire, Domaine du Sart Tilman, 4000 Liège, Belgium 1/1 004 Dr Claude Hanet/Cliniques Universitaires St Luc, Service de Cardiologie, 10 avenue Hippocrate, 1200 Brussels, Belgium 0/0 005 PD Dr Willenbrock/Krankenhaus St Elisabeth und St Barbara, Klinik für Innere Medizin II, Mauerstrasse 5, Postfach 20 02 54, 06110 Halle (Saale), Germany 12/12 006 Dr Rainer Wessely Deutsches Herzzentrum München des Freistaates Bayern, Munich, Germany 4/4 007 Dr Marcus Wiemer/Herz- und Diabeteszentrum Nordrhein-Westfalen, Kardiologische Klinik, Georgstrasse 11, 32545 Bad Oeynhausen, Germany 29/27 008 Dr Rémi Sabatier/CHU Cote de Nacre, Service de Cardiologie, 14033 Caen Cedex, France 5/5 009 Prof Dr Ruth Strasser/Medizinische Klinik/Kardiologie, Technische Universität Dresden, Fetscherstrasse 76, 01307 Dresden, Germany 14/14 010 Dr Pierre Aubry/Hôpital Bichat, Service de Cardiologie B, 46, rue Henri Huchard, 75018 Paris, France 6/6 011 Dr Azfar Zaman/Freeman Hospital, Freeman Road, Newcastle NE7 7DN, UK 7/7 012 Centre withdrawn – 013 Dr Thorsten Dill/Kerckhoff-Klinik GmbH, Benekestrasse 2-8, 61231 Bad Nauheim, Germany 9/9 014 Dr Eulogio García/Hospital Gregorio Marañón, Cardiology Dept, Doctor Esquerdo, 46, 28007 Madrid, Spain 4/4 015 Dr Franscisco Fernández-Avilés/Hospital Universitario de Valladolid, Cardiology Dept, Avda Ramón y Cajal, 3, 47011 Valladolid, Spain 10/10 016 Dr Paolo Rubartelli, Ospedale Villascassi, Corso Scassi, 16126 Genova, Italy 5/5 017 Centre withdrawn – 018 Dr Charles Knight/The London Chest Hospital, Bonner Road, Bethnal Green, London E2 9JX, UK 0/0 019 Dr Joachim Schümmelfeder (until July 1, 2006), Dr Frank Gietzen (from July 1, 2006)/Herz- und Gefäss-Klinik GmbH, Salzburger Leite 1, 97616 Bad Neustadt/Saale, Germany 19/19 020 Prof Dr Franz-Josef Neumann/Herzzentrum Bad Krozingen, Am Südring 15, 79189 Bad Krozingen, Germany 14/14 021 Dr Jacques Boschat/CHU de Brest-Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, 29 200 Brest cedex, France 1/1 022 Dr Michael Rosseel/Algemeen Stedelijk Ziekenhuis, Cardiologie, Merestraat 80, 9300 Aalst, Belgium 0/0 023 Dr Marc Vincent/Brussels Heart Centre, Clinique Générale St Jean, 32 bd du Jardin Botanique, 1000 Brussels, Belgium 7/7 024 Dr Mathias Vrolix/ZOl-Campus St Jan, Cardiology department, Schiepsebos 6, 3600 Genk, Belgium 4/4 025 Prof Ludwig Thierfelder/Franz-Volhard-Klinik, Charitè Campus Berlin-Buch, Wiltbergstrasse 50, 13125 Berlin, Germany 9/9 026 PD Dr Stefan Sack/Universitätsklinikum Essen, Zentrum für Innere Medizin, Klinik für Kardiologie, Westdeutsches Herzzentrum Essen, Hufelandstrasse 55, 45122 Essen, Germany 0/0 027 Dr Antonio Manari/Azienda Ospedaliera Arcispedale Santa Maria Nuova di Reggio Emilia, Struttura Complessa di Diagnostica e Interventistica Cardiologia, Viale Risorgimento, 80, 42100 Reggio Emilia, Italy 5/5 028 Dr Nick Ossei-Gerning/University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK 2/2 029 Dr Matthias R. Schulze/Klinikum Schwalmstadt, Schwalm-Eder-Kliniken GmbH, Krankenhausstrasse 27, 34613 Schwalmstadt, Germany 18/18 030 Prof Forster Tamás/Szegedi Orvostudományi Egyetem, Kardiológiai Centrum, Korányi fasor 6, 6720 Szeged, Hungary 6/5 031 Dr Lupkovics Géza/Zala Megyei Kórház, Kardiológiai Osztály, Zrínyi Miklós u. 1, 8900 Zalaegerszeg, Hungary 7/7 032 Dr Apró Dezsõ/Állami Szívkórház Balatonfüred, 1. sz. Kardiológiai Osztály, Gyógy tér 2, 8230 Balatonfüred, Hungary 10/10 033 Prof. Tomasz Pasierski/Miedzyleski Szpital Specjalistyczny, Oddzial Kardiologii, Ul. Bursztynowa 2, 04-749 Warszawa, Poland 14/14 034 Prof Slawomir Dobrzycki/Samodzielny Publiczny Szpital Kliniczny AM w Bialymstoku, Zaklad Kardiologii Inwazyjnej, Ul. M. Sklodowskiej-Curie 24A, 15-276 Bialystok, Poland 16/15 035 Prof. Waldemar Banasiak/4 Wojskowy Szpital Kliniczny, Osrodek Chorób Serca, Ul. Weigla 5, 53-114 Wroclaw, Poland 12/12 101 Warren Laskey, MD ‡ /The University of New Mexico Health Science Center School of Medicine, Department of Internal Medicine MSC10-5550, 1 University of New Mexico, Albuquerque, NM 87131, USA 19/17 D Michelle Ratliff, MD/Albuquerque Veterans Affairs Med ical Center, 1501 San Pedro SE, Albuquerque, NM 87108, USA 102 Charles J. Davidson, MD/251 East Huron Street, Feinberg 8-256, Chicago, IL 60611, USA 26/26 103 Michael Rudnick, MD/Renal Electrolyte and Hypertension Division, Penn Presbyterian Medical Center, 240 Medical Office Building, 39th and Market St, Philadelphia, PA 19104, USA 9/9 104 Reda Ibrahim, MD/Montreal Heart Institute, 5000 East Belanger Street, Roulotte 1000A, Montréal, Québec, H1T 1C8, Canada 13/13 105 Center did not participate – 106 Steven Rohrbeck, MD/Carolina Cardiology Associates, 306 Westwood Ave, Ste 401, High Point, NC 27262, USA 13/13 107 J. Lawrence Stafford, MD/University of Maryland Medical Center, 22 S Greene St, Room S3B08, Baltimore, MD 21201, USA 11/10 108 Edward O. McFalls, MD/Minneapolis Veterans Affairs Medical Center, One Veterans Dr, Cardiology 111C, Minneapolis, MN 55417, USA 13/13 109 Kendrick Shunk, MD/San Francisco Veterans Affairs Medical Center, 4150 Clement St, Mail Stop 151 CRC, San Francisco, CA 94121, USA 3/3 110 Frederick Weiland, MD/Sutter Roseville Medical Center, One Medical Plaza, Roseville, CA 95661, USA 0/0 111 Gary Schaer, MD/Rush University Medical Center, 1653 W Congress Pkwy, Ste 1035 Jelke, Chicago, IL 60612, USA 12/11 112 J. Huger Richardson, MD/South Carolina Heart Center, 2001 Laurel St, Columbia, SC 29204, USA 1/1 113 Peter C. Nishan, MD/LeBauer Cardiovascular Research Foundation, 1126 N Church St, Ste 300, Greensboro, NC 27401, USA 7/7 114 Christian Bounds, MD/Delmarva Heart Research Foundation, Inc, 106 Milford St, Ste 605, Salisbury, MD 21804, USA 10/10 115 Maurice Buchbinder, MD/Foundation for Cardiovascular Medicine, 9834 Genesee Ave, Ste 310, La Jolla, CA 92037, USA 0/0 116 Jesse Goldman, MD/Temple University Hospital, Parkinson Pavilion 658, 3401 N Broad St, Philadelphia, PA 19140, USA 10/10 117 Anthony Fung, MD/The University of British Columbia, Vancouver Hospital (VCH), Interventional Cardiology Research, 9176-2775 Laurel St, Vancouver, BC V5Z 1M9, Canada 15/15 118 Center withdrawn – 119 John Hirshfeld, MD/University of Pennsylvania Medical Center, 9.119 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, USA 12/12 120 Joseph Moore, MD/Jacksonville Center for Clinical Research, 4085 University Blvd South, Ste 1, Jacksonville, FL 32216, USA 4/3 121 Steven Weisbord, MD, MSc/University of Pittsburgh, 200 Lathrop St, Pittsburgh, PA 15213, USA 15/14 122 Steven Weisbord, MD, MSc/VA Pittsburgh Healthcare System, University Drive Division (111F-U), Room 7E 120, Pittsburgh, PA 15240, USA 1/1 123 Lee A. MacDonald, MD, South Denver Cardiology Associates, PC, 1000 Southpark Dr, Littleton, CO 80120, USA 4/4 124 Anjali Acharya, MD, Jacobi Medical Center, North Bronx Healthcare Network, 1400 Pelham Parkway South, 6E-23B, Bldg I, Box 10461, Bronx, NY 10461, USA 4/4 125 John Colleran, MD, The Heart & Vascular Institute of Florida, 6006 49th St North, Ste 200, St Petersburg, Fl 33709, USA 1/1 201a Dr V Seshiah/Dr V Seshiah Diabetes Care and Research Institute, 31/A, Ormes Road Kilpauk, Chennai-600 010, Tamil Nadu, India 0/0 202a Dr Vijay Viswanathan/Diabetes Research Centre & Hospital For Diabetes, 4, West Mada Church Street, Royapuram, Chennai-600 013, Tamil Nadu, India 0/0 203 Dr Shreenivas Kumar/CARE Hospital, Road #1, Banjara Hills, Hyderabad-500 034, Andhra Pradesh, India 46/46 204 Dr Parthap Kumar (MD, DM FIC)/Manipal Hospital, Airport Road, 98 Rustumbagh, Bangalore-560 017, India 18/18 205 Dr Pramod Jaiswal/Institute of Cardiac Vascular Disease, R-30-C, Ambattur Industrial Estate Road, Chennai-600 101, Tamil Nadu, India 16/14 ⁎ Assigned a subject study number. † Coordinating investigator, Europe and India. ‡ Coordinating investigator, North America.
PY - 2009/11
Y1 - 2009/11
N2 - Background: The choice of radiographic contrast media for use in patients at increased risk of contrast-induced nephropathy (CIN) is of ongoing interest. Methods: The current study is a prospective, multicenter, randomized, double-blind design comparing the renal effects of the non-ionic, iso-osmolal agent, iodixanol, versus the non-ionic, low-osmolal agent, iopamidol, in 526 subjects with impaired baseline renal function (chronic kidney disease) and diabetes mellitus undergoing diagnostic and/or therapeutic coronary angiographic procedures. The co-primary end points were the peak increase in serum creatinine (SCr) and the incidence of CIN (increase ≥0.5 mg/dL) in SCr from baseline within 3 days of receiving contrast media. Results: In 418 evaluable subjects with complete postcontrast media SCr data, the median peak increase in SCr in the iodixanol arm was 0.10 mg/dL, whereas in the iopamidol arm, the median peak increase was 0.09 mg/dL (P = .13). The overall CIN incidence was 10.5% (11.2% % in the iodixanol arm and 9.8% in the iopamidol arm, P = .7). The volume of contrast media, volume of saline administered, frequency of coronary interventional procedures, and severity of baseline kidney disease and of diabetes mellitus were similar between treatments. Conclusions: In the present study, the overall rate of CIN in patients with chronic kidney disease and DM undergoing coronary angiographic procedures was 10.5%. There was no significant difference between iodixanol and iopamidol in either peak increase in SCr or risk of CIN.
AB - Background: The choice of radiographic contrast media for use in patients at increased risk of contrast-induced nephropathy (CIN) is of ongoing interest. Methods: The current study is a prospective, multicenter, randomized, double-blind design comparing the renal effects of the non-ionic, iso-osmolal agent, iodixanol, versus the non-ionic, low-osmolal agent, iopamidol, in 526 subjects with impaired baseline renal function (chronic kidney disease) and diabetes mellitus undergoing diagnostic and/or therapeutic coronary angiographic procedures. The co-primary end points were the peak increase in serum creatinine (SCr) and the incidence of CIN (increase ≥0.5 mg/dL) in SCr from baseline within 3 days of receiving contrast media. Results: In 418 evaluable subjects with complete postcontrast media SCr data, the median peak increase in SCr in the iodixanol arm was 0.10 mg/dL, whereas in the iopamidol arm, the median peak increase was 0.09 mg/dL (P = .13). The overall CIN incidence was 10.5% (11.2% % in the iodixanol arm and 9.8% in the iopamidol arm, P = .7). The volume of contrast media, volume of saline administered, frequency of coronary interventional procedures, and severity of baseline kidney disease and of diabetes mellitus were similar between treatments. Conclusions: In the present study, the overall rate of CIN in patients with chronic kidney disease and DM undergoing coronary angiographic procedures was 10.5%. There was no significant difference between iodixanol and iopamidol in either peak increase in SCr or risk of CIN.
UR - http://www.scopus.com/inward/record.url?scp=70350173723&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350173723&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2009.08.016
DO - 10.1016/j.ahj.2009.08.016
M3 - Article
C2 - 19853704
AN - SCOPUS:70350173723
VL - 158
SP - 822-828.e3
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 5
ER -